Antimicrobial resistance (AMR) is rapidly becoming a global crisis that could claim 40 million lives by 2050. In this video, we explore why pharmaceutical companies are reluctant to develop new ...

Did you know that back in the 1980s and '90s, when South Korea was on the road toward becoming—but had yet to become—the ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

In this episode of the State of Economy Podcast, businessline’s Jyothi Datta speaks with Sudharshan Jain, the Secretary General of the Indian Pharmaceutical Alliance (IPA), as they reflect on ...

Nonribosomal peptide synthetase (NRPS) enzymes are essential in creating important medications, such as penicillin and ...

Researchers at McMaster University have discovered a critical vulnerability in drug-resistant bacteria: zinc -- or a lack thereof. In a recent study, published in the journal Nature Microbiology, ...

Researchers at Dalhousie and the University of Toronto, working with the pharmaceutical company DeNovaMed Inc., are addressing that threat head-on with the development of a new family of antibiotics ...

“In response to the growing global demand for new antibiotics, AstraZeneca is one of the few large pharmaceutical companies involved in the research and development of new therapies addressing ...

Double whammy antibiotic makes antibiotic resistance much harder—new study Aug 5, 2024 Researchers find degradation of cell wall key in the spread of resistance ...

A team of researchers at the Helmholtz Institute for Pharmaceutical Research Saarland ... with far-reaching consequences is the transfer of antibiotic resistance genes between bacterial pathogens.